8-K: Altimmune Sets 2026 Annual Meeting Date, Updates Deadlines
Annual Meeting Update
Altimmune, Inc. announced the date for its 2026 Annual Meeting of Stockholders and updated deadlines for stockholder proposals and director nominations.
Summary
- Altimmune, Inc. has set Thursday, April 16, 2026, as the date for its 2026 Annual Meeting of Stockholders.
- The meeting date was changed to align with the standard second-quarter annual meeting calendar for companies with a December 31 fiscal year-end.
- The record date for stockholders entitled to vote at the 2026 Annual Meeting is the close of business on Friday, March 13, 2026.
- The meeting is expected to be virtual, consistent with previous years.
- Due to the change in the annual meeting date, the deadline for stockholder proposals under Rule 14a-8 is February 13, 2026.
- The deadline for director nominees or other proposals submitted under the company's bylaws is also February 13, 2026.
- Stockholders intending to solicit proxies for director nominees must provide notice by February 15, 2026, to comply with universal proxy rules.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, procedural announcement regarding corporate governance, with no direct impact on the company's financial performance or strategic direction.
Future Outlook
The company expects to specify the exact time and location of the 2026 Annual Meeting in its proxy statement and anticipates it will be a virtual meeting, consistent with prior years.
Industry Context
StockSavvy.ai notes that aligning annual meeting dates with standard fiscal year-end calendars is a common corporate practice, enhancing predictability for investors and streamlining corporate governance processes across the industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Annual Meeting Date | The 2026 Annual Meeting of Stockholders is set for April 16, 2026, aligning with a standard second-quarter calendar for 12/31 fiscal year-end companies. This differs by more than 30 days from the anniversary of the 2025 meeting. | 2026-04-16 | Provides greater predictability for investors and aligns with industry norms for annual meeting scheduling. |
| Stockholder Proposal Deadlines | New deadlines for stockholder proposals under Rule 14a-8 (February 13, 2026), director nominations/proposals under bylaws (February 13, 2026), and universal proxy rule notices (February 15, 2026) have been established due to the change in the annual meeting date. | 2026-02-02 | Clarifies the timeline for stockholder engagement and ensures compliance with SEC regulations for proxy solicitations. |
Stakeholder Impact
- Shareholders: Impacted by the new deadlines for submitting proposals and director nominations, and the new record date for voting eligibility.
- Management: Ensures compliance with SEC regulations and corporate bylaws regarding annual meetings and proxy solicitations.
Next Steps
- The company will specify the exact time and location of the 2026 Annual Meeting in its upcoming proxy statement.
Key Dates
| Date | Description |
|---|---|
| 2025-09-25 | Date of the 2025 Annual Meeting of Stockholders. |
| 2026-02-02 | Date of earliest event reported in the 8-K filing. |
| 2026-02-03 | Date the 8-K report was signed by the Chief Financial Officer. |
| 2026-02-13 | Deadline for stockholder proposals under Rule 14a-8 for inclusion in the proxy statement. |
| 2026-02-13 | Deadline for director nominees or other proposals submitted by stockholders under the company's bylaws. |
| 2026-02-15 | Deadline for stockholders to provide notice for soliciting proxies in support of director nominees under universal proxy rules (Rule 14a-19). |
| 2026-03-13 | Record date for stockholders entitled to receive notice of and vote at the 2026 Annual Meeting. |
| 2026-04-16 | Date of the 2026 Annual Meeting of Stockholders. |
Keywords
Altimmune, ALT, Annual Meeting, Stockholder Meeting, Proxy Statement, Corporate Governance, SEC Filing, 8-K, Shareholder Proposals, Director Nominations
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.